全球血液產業 是由出版商BCC Research在2011年03月所出版的。
這份英文市場調查報告書包含197 Pages 價格從美金4850起跳。
抽血、血型鑑定、血液處理、輸血、血液治療等全球血液市場，於2010年預計可由300億美金以CAGR8.4%持續成長，並於2015年達到450億美金之市場規模。而包含免疫球蛋白、凝血因子、白蛋白、纖維蛋白等血液治療產品之區隔，也預估將由2010年約160億美金以10.8%之CAGR成長，達到2015年260億美金之市場規模。
本報告為，調查分析全球血液產業現況及展望，並匯整血液產業結構、市場規模變化及預測（∼2015年）、各市場區隔分析及展望、血液使用模式及趨勢、相關法規、市場企業及相對市場佔有率、目前產品線、新產品及技術之探討、相關專利趨勢等，以下列摘要形式闡述。
第1章 簡介
第2章 摘要
第3章 概要
- 血液產業之歷史
- 捐血動態
- 抽血、血液處理之市場結構及規模
- 血液及其組成要素
- 輸血風險
- 脫毒之供血
- 輸血之負面反應
- 血液/血漿之結構風險因素
第4章 抽血、血型鑑定、血液處理
- 抽血
- 抽血方式
- 抽血市場之成長因素
- 美國捐血人口統計
- 全球抽血活動
- 全球之血漿產業
- 血型鑑定
- 輸血檢測
- 血液處理
- 全球血液管理挑戰
第5章 血液治療
- 全血
- 濃縮紅細胞
- 血小板
- 白細胞
- 新鮮冰凍血漿
- 冷沉澱
- 洗滌細胞
- 甘油細胞去除
- 其他血液成分
- 抽血分布
- 血液/血漿類產品
- 全球血漿採集
- 血漿市場規模
- 凝血因子
- 白蛋白
- 凝血酶及纖維蛋白
- 抗凝血酶治療
- 全球抗凝血酶市場
- 免疫球蛋白
第6章 血液產業相關法規
- 美國血液產業相關法規
- 美國供血主要法規及政策
- EU之政策
- ISBT（THE INTERNATIONAL SOCIETY FOR BLOOD TRANSFUSION）
- 日本之法規
- 中國之法規
- 全球血液相關法規之未來
第7章 血液產品技術
- 分離技術
- 擴增法
- 免疫分析
- 凝聚
- 化學發光（CHLIA）
- 內毒素檢測
第8章 研究開發
- JEROME H. HOLLAND LABORATORY (ARC)
- NATIONAL BLOOD FOUNDATION (NBF)
- CENTER FOR BLOOD RESEARCH (CBR)
- FDA之血液研究
- 美國國外之幹細胞開發
- 創新生物工程技術
- 阿滋海默症及肝硬化之研究
- 血液替代品目前之研究
- 新的血小板治療
- 獸醫用血液市場
第9章 專利
第10章 企業簡介
圖表
Abstract
REPORT HIGHLIGHTS
- The global blood market includes products used for collecting, typing,
processing, and transfusing of blood and the sale of blood therapeutics. This
market was worth $30 billion in 2010 and is forecast to increase at an 8.4%
compound annual growth rate (CAGR) to reach $45 billion in 2015.
- Blood therapeutic products, including immunoglobulins, coagulation
factors, albumin, fibrin sealants, and antithrombin products, are projected to
grow at a compound annual growth rate (CAGR) of 10.8% over the 5-year forecast
period. This sector was valued at nearly $16 billion in 2010 and is expected
to reach $26 billion in 2015.
- Sales for blood processing, collection, and typing/testing reached $14
billion in 2010. This market is forecast to grow at a 5.5% compound annual
growth rate (CAGR) to reach more than $18 billion in 2015.
SUMMARY FIGURE
GLOBAL BLOOD MARKET, BY REGION, 2010 AND 2015
(%)
Source: BCC Research
REPORT SCOPE
INTRODUCTION
REASONS FOR DOING THE STUDY
A safe and adequate blood supply is essential to the practice of modern
medicine. Ensuring adequate supplies of trustworthy blood and derivative
products has lead nations and companies to create a multibillion-dollar
business that reaches around the globe.
The global blood industry encompasses the collection, typing, testing, and
processing of blood and the creation of blood derivatives to help individuals
with varying blood problems. The purpose of this study is to detail advances
in these areas and their impact on the blood industry.
During the past 10 years, since BCC first looked at this market, mergers and
acquisitions have created an industry dominated by less than 10 major
companies. This consolidation and advances in technology have allowed
industry participants to obtain more red blood cells from fewer donors.
Technological advances have also allowed for greater economies and increased
safety in the blood supply.
STUDY GOALS AND OBJECTIVES
With its broad scope and in-depth analyses, this study will be a valuable
resource to anyone involved with or interested in the blood industry. This
study will provide information on:
- Structure and current market size of the blood industry, with forecasts
through 2015
- Analysis and projections of various segments of the industry such as
collection, typing, testing, and blood therapeutics
- Blood usage patterns and trends
- Government and regulatory controls
- Impact of diseases on the blood industry
- Major players and their relative market shares and market potential
- Current product lines and examination of newly emerging products and
technologies
- State of the international markets for various blood and blood-related
products
- Newly issued patents relating to blood therapeutics, processing,
screening, and collection technologies.
The study will prove valuable to a variety of readers, including industry
executives, managers and planners, researchers, industry analysts, and
investors. The projections, forecasts, and trend analyses found in this
report provide readers with the necessary data and information for careful
decision- making.
SCOPE OF REPORT
This report offers global and U.S. projections, by product segment, from 2010
through 2015, including supporting analyses for projections. Product segments
covered consist of blood and plasma collection, blood and plasma processing,
blood therapeutic products, plasma therapeutic products, and emerging trends
and products.
The arrangement of this report offers an overview of the key elements in the
blood collection and processing businesses: blood typing techniques and
markets, and plasma fractionation. International markets are discussed, and
information is provided on industry structure and the regulatory environment
outside the U.S.
Profiles of more than 30 leading companies involved with blood collection,
processing, and therapeutics are included. The report provides information on
company placement within the market and strategic analyses of the companies'
available and emerging products.
METHODOLOGIES AND INFORMATION SOURCES
Information for this report was derived from a variety of primary and
secondary research sources, including industry analysts, annual reports and
SEC reports, the American Red Cross (ARC), the American Association of Blood
Banks (AABB), the Plasma Protein Therapeutics Association (PPTA), the National
Institutes of Health (NIH), the Centers for Disease Control (CDC), other
government agencies, and journal articles. Secondary sources include
literature searches, product literature, and press releases.
When precise information was not available, a consensus was made using
reasonable assumptions and estimates based on historical data.
Table of Contents
Chapter- 1: INTRODUCTION - Complimentary
- REASONS FOR DOING THE STUDY
- STUDY GOAL AND OBJECTIVES
- SCOPE OF REPORT
- METHODOLOGIES AND INFORMATION SOURCES
- ANALYST CREDENTIALS
- RELATED BCC REPORTS
- BCC ONLINE SERVICES
- DISCLAIMER
Chapter- 2: SUMMARY
- MAJOR FINDINGS
- Table 0 : GLOBAL BLOOD COLLECTION, PROCESSING, AND THERAPEUTICS MARKET,
THROUGH 2015
- Figure 0 : GLOBAL BLOOD MARKET, BY REGION, 2010 AND 2015
Chapter- 3: OVERVIEW
- HISTORY OF THE BLOOD INDUSTRY
- DYNAMICS OF BLOOD DONATION
- BLOOD COLLECTION AND PROCESSING MARKET STRUCTURE AND SIZE
- BLOOD AND ITS COMPONENTS
- TRANSFUSION-ASSOCIATED RISKS
- CREATING A VIRUS-FREE BLOOD SUPPLY
- NEGATIVE REACTIONS FROM BLOOD TRANSFUSIONS
- BLOOD/PLASMA COMPONENT RISKS
Chapter- 4: BLOOD COLLECTION, TYPING, AND PROCESSING
- BLOOD COLLECTION
- METHODS FOR COLLECTING BLOOD
- MARKET DRIVERS IN BLOOD COLLECTION
- U.S. BLOOD DONATION DEMOGRAPHICS
- BLOOD COLLECTION EFFORTS THROUGHOUT THE WORLD
- GLOBAL NATURE OF THE PLASMA INDUSTRY
- BLOOD TYPING
- BLOOD TRANSFUSION TESTING
- BLOOD PROCESSING
- GLOBAL BLOOD MANAGEMENT ISSUES
Chapter- 5: BLOOD THERAPEUTICS
- WHOLE BLOOD
- PACKED RED BLOOD CELLS
- PLATELETS
- LEUKOCYTES
- FRESH FROZEN PLASMA
- CRYOPRECIPITATE
- WASHED CELLS
- DEGLYCEROLIZED CELLS
- OTHER BLOOD COMPONENTS
- DISTRIBUTION OF COLLECTED BLOOD
- PLASMA AND PLASMA-DERIVED PRODUCTS
- GLOBAL PLASMA COLLECTION
- PLASMA MARKET SIZE
- COAGULATION FACTORS
- ALBUMIN
- FIBRIN SEALANTS AND THROMBIN
- ANTITHROMBIN TREATMENTS
- GLOBAL MARKET FOR ANTITHROMBIN
- IMMUNOGLOBULINS
- Table 41 : FDA-APPROVED IMMUNOGLOBULINS
- Table 42 : PROJECTED GLOBAL MARKET FOR IMMUNOGLOBULINS, THROUGH 2015
Chapter- 6: BLOOD INDUSTRY REGULATION
- REGULATION OF THE U.S. BLOOD BUSINESS
- MAJOR REGULATIONS AND POLICIES FOR THE U.S. BLOOD SUPPLY
- EUROPEAN UNION (EU) REGULATIONS
- THE INTERNATIONAL SOCIETY FOR BLOOD TRANSFUSION (ISBT) 128
- REGULATION IN JAPAN
- REGULATION IN CHINA
- THE FUTURE OF GLOBAL BLOOD REGULATIONS
Chapter- 7: BLOOD PRODUCTS TECHNOLOGY
- FRACTIONATION METHODS
- AMPLIFICATION METHODS
- IMMUNOASSAY METHODS
- AGGLUTINATION
- CHEMILUMINESCENCE (CHLIA)
- ENDOTOXIN TESTING
Chapter- 8: BLOOD RESEARCH AND DEVELOPMENT
- JEROME H. HOLLAND LABORATORY (ARC)
- NATIONAL BLOOD FOUNDATION (NBF)
- CENTER FOR BLOOD RESEARCH (CBR)
- FDA BLOOD RESEARCH PRODUCTS
- STEM CELL DEVELOPMENTS OUTSIDE THE U.S.
- NOVEL BIOENGINEERING TECHNOLOGIES
- RESEARCH ON ALZHEIMER' S AND CIRRHOSIS OF THE LIVER
- CURRENT RESEARCH ON BLOOD SUBSTITUTES
- EMERGING PLATELET TREATMENTS
- THE VETERINARY BLOOD MARKET
- Table 59 : REGIONAL U.S. VETERINARY BLOOD BANKS
Chapter- 9: PATENTS
- Table 60 : RECENTLY ISSUED PATENTS, JANUARY 2005 THROUGH JANUARY 2011
- Table 61 : PATENTS BY COMPANY ASSIGNEE, JANUARY 2005 THROUGH JANUARY 2011
- Table 62 : PATENTS ISSUED BETWEEN 2005 AND 2011: PLASMA DERIVATIVES
- Table 63 : PATENTS ISSUED BETWEEN 2005 AND 2011: BLOOD COLLECTION,
SAMPLING EQUIPMENT
- Table 64 : PATENTS ISSUED BETWEEN 2005 AND 2011: BLOOD FILTRATION, FLUID
SEPARATION EQUIPMENT
- Table 65 : PATENTS ISSUED BETWEEN 2005 AND 2011: BLOOD VOLUME ENHANCERS
- Table 66 : PATENTS ISSUED BETWEEN 2005 AND 2011: NUCLEIC ACID AMPLIFICATION
- Table 67 : PATENTS ISSUED BETWEEN 2005 AND 2011: BLOOD TREATMENTS
- Table 68 : PATENTS ISSUED BETWEEN 2005 AND 2011: ADDITIONAL POTENTIAL
PRODUCTS
Chapter- 10: COMPANY PROFILES
- ABBOTT LABORATORIES
- ALPHA THERAPEUTICS CORP.
- AMERICA' S BLOOD CENTERS
- AMERICAN ASSOCIATION OF BLOOD BANKS (AABB)
- AMERICAN RED CROSS
- BAXTER INTERNATIONAL, INC.
- BECKMAN COULTER
- BECTON DICKINSON AND COMPANY
- BIO PRODUCTS LABORATORIES
- BIO-RAD LABORATORIES, INC.
- BIOTEST AG
- CARIDIANBCT INC.
- CERUS CORP.
- CHIRON CORP. (SEE NOVARTIS DIAGNOSTICS)
- CSL BEHRING
- DAXOR CORP.
- DIAGAST
- FENWAL BLOOD TECHNOLOGIES, INC.
- FRESENIUS KABI AG
- GEN-PROBE, INC.
- GRIFOLS BIOLOGICALS, INC.
- HAEMONETICS, INC.
- HEMAGEN DIAGNOSTICS, INC.
- HEMOCUE AB
- IMMUCOR, INC.
- KAWASUMI LABORATORIES, INC.
- LUMINEX CORPORATION
- MACOPHARMA USA (FORMERLY UNITED PHARMA)
- MASSACHUSETTS PUBLIC HEALTH BIOLOGIC LABS
- NOVARTIS DIAGNOSTICS
- NOVO NORDISK
- OCTAPHARMA
- OLYMPUS AMERICA, INC. (SEE BECKMAN COULTER)
- ONE LAMBDA, INC.
- ORTHO-CLINICAL DIAGNOSTICS
- PALL CORP.
- PFIZER
- TALECRIS BIOTHERAPEUTICS
- TERUMO MEDICAL CORP.
- THERMOGENESIS CORP.
List of Tables
- Table 1 : TIMELINE OF THE BLOOD INDUSTRY
- Table 2 : SELECTED ACQUISITIONS AND MERGERS IN THE GLOBAL BLOOD INDUSTRY,
2006-2011
- Table 3 : U.S. BLOOD COLLECTION AND PROCESSING PRODUCTS MARKET, THROUGH
2015
- Table 4 : COMPOSITION OF BLOOD
- Table 5 : PERCENT OF PLASMA PROTEINS AND THE DISEASES AND DISORDERS THEY
TREAT
- Table 6 : DISEASES CONTRACTED FROM BLOOD TRANSFUSIONS
- Table 7 : CBER-LICENSED HIV DONOR SCREENING TESTS
- Table 8 : CBER-LICENSED SCREENING TEST FOR HEPATITIS B
- Table 9 : CBER-LICENSED SCREENING TESTS FOR HEPATITIS C
- Table 10 : CBER-LICENSED SCREENING TESTS FOR HTLV-I AND HTLV-II
- Table 11 : CBER-LICENSED SCREENING TESTS FOR CMV
- Table 12 : CBER-LICENSED SCREENING TESTS FOR WEST NILE VIRUS
- Table 13 : CBER-LICENSED SCREENING TESTS FOR SYPHILIS
- Table 14 : CBER-LICENSED SCREENING TESTS FOR TRYPANOSOMA CRUZI (CHAGAS
DISEASE)
- Table 15 : CBER-LICENSED SCREENING TEST, BY TYPE
- Table 16 : PROJECTED GLOBAL MARKET FOR BLOOD/PLASMA COLLECTION, TYPING AND
TESTING, AND PROCESSING EQUIPMENT AND SUPPLIES, THROUGH 2015
- Table 17 : PROJECTED GLOBAL MARKET FOR MANUAL AND AUTOMATIC BLOOD
COLLECTION EQUIPMENT AND SUPPLIES, THROUGH 2015
- Table 18 : PROJECTED GLOBAL MARKET FOR AUTOMATED BLOOD SALVAGE EQUIPMENT,
THROUGH 2015
- Table 19 : PROJECTED GLOBAL MARKET FOR BLOOD BAGS, THROUGH 2015
- Table 20 : PROJECTED GLOBAL MARKET FOR BLOOD FILTERS, THROUGH 2015
- Table 21 : PROJECTED GLOBAL MARKET FOR OTHER COLLECTION EQUIPMENT
INCLUDING BLOOD TRANSFUSION SETS AND ACCESSORIES, THROUGH 2015
- Table 22 : TESTS ROUTINELY PERFORMED ON BLOOD DONATIONS
- Table 23 : BLOOD TYPE ANTIGEN/ANTIBODY REACTIONS
- Table 24 : PROJECTED GLOBAL MARKET FOR BLOOD TYPING AND TESTING, BY
GEOGRAPHICAL AREA, THROUGH 2015
- Table 25 : BLOOD PRODUCTS TRANSFUSED FOR THEIR THERAPEUTIC USES
- Table 26 : AVERAGE COST OF TRANSFUSION TO THE PATIENT IN THE U.S., BY
PRODUCT TYPE, 2011
- Table 27 : PROJECTED GLOBAL PLASMA MARKET, THROUGH 2015
- Table 28 : BLOOD CLOTTING FACTORS
- Table 29 : GLOBAL PREVALENCE OF HEMOPHILIA, 2009
- Table 30 : PROJECTED GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT
CLOTTING FACTORS, THROUGH 2015
- Table 31 : FDA-APPROVED FACTOR VIII PRODUCTS
- Table 32 : PROJECTED U.S. MARKET FOR FACTOR VIII, THROUGH 2015
- Table 33 : PROJECTED GLOBAL MARKET FOR FACTOR IX, THROUGH 2015
- Table 34 : FDA-APPROVED FACTOR IX PRODUCTS, 2009
- Table 35 : PROJECTED GLOBAL MARKET FOR FACTOR VIIA, THROUGH 2015
- Table 36 : CURRENTLY MARKETED HUMAN ALBUMIN AND PPF PRODUCTS, 2010
- Table 37 : PROJECTED GLOBAL MARKET FOR HUMAN SERUM ALBUMIN AND PPF,
THROUGH 2015
- Table 38 : FDA-APPROVED PROTHROMBIN COMPLEX CONCENTRATE PRODUCTS
- Table 39 : PROJECTED GLOBAL MARKET FOR FIBRIN-BASED SEALANTS, THROUGH 2015
- Table 40 : PROJECTED GLOBAL MARKET FOR ANTITHROMBIN, THROUGH 2015
- Table 41 : FDA-APPROVED IMMUNOGLOBULINS
- Table 42 : PROJECTED GLOBAL MARKET FOR IMMUNOGLOBULINS, THROUGH 2015
- Table 43 : SELECTED CONDITIONS TREATED WITH IVIG
- Table 44 : PROJECTED GLOBAL MARKET FOR IVIG THERAPY, THROUGH 2015
- Table 45 : FDA-APPROVED HYPERIMMUNE IMMUNOGLOBULINS
- Table 46 : PROJECTED GLOBAL MARKET FOR HYPERIMMUNOGLOBULINS, THROUGH 2015
- Table 47 : PROJECTED GLOBAL MARKET FOR RSV IMMUNOGLOBULIN, THROUGH 2015
- Table 48 : PROJECTED GLOBAL MARKET FOR ALPHA-1-PROTEINASE INHIBITOR,
THROUGH 2015
- Table 49 : PROJECTED GLOBAL MARKET FOR RHO(D), THROUGH 2015
- Table 50 : PROJECTED GLOBAL MARKET FOR HBV IMMUNOGLOBULINS, THROUGH 2015
- Table 51 : PROJECTED GLOBAL MARKET FOR CMV IMMUNOGLOBULIN, THROUGH 2015
- Table 52 : PROJECTED GLOBAL MARKET FOR TETANUS IMMUNOGLOBULIN, THROUGH 2015
- Table 53 : PROJECTED GLOBAL MARKET FOR RABIES IMMUNOGLOBULIN, THROUGH 2015
- Table 54 : U.S. FEDERAL ORGANIZATIONS RESPONSIBLE FOR BLOOD SAFETY
- Table 55 : FDA AUTHORITY IN REGULATING BLOOD BANKING AND BLOOD PRODUCTS
- Table 56 : MAIN BLOOD REGULATION ISSUES IDENTIFIED BY THE FDA
- Table 57 : 14 MAJOR AREAS OF CONCERN FOR INSPECTING BLOOD FACILITIES
- Table 58 : SELECTED BLOOD RESEARCH FROM FDA, 2010
- Table 59 : REGIONAL U.S. VETERINARY BLOOD BANKS
- Table 60 : RECENTLY ISSUED PATENTS, JANUARY 2005 THROUGH JANUARY 2011
- Table 61 : PATENTS BY COMPANY ASSIGNEE, JANUARY 2005 THROUGH JANUARY 2011
- Table 62 : PATENTS ISSUED BETWEEN 2005 AND 2011: PLASMA DERIVATIVES
- Table 63 : PATENTS ISSUED BETWEEN 2005 AND 2011: BLOOD COLLECTION,
SAMPLING EQUIPMENT
- Table 64 : PATENTS ISSUED BETWEEN 2005 AND 2011: BLOOD FILTRATION, FLUID
SEPARATION EQUIPMENT
- Table 65 : PATENTS ISSUED BETWEEN 2005 AND 2011: BLOOD VOLUME ENHANCERS
- Table 66 : PATENTS ISSUED BETWEEN 2005 AND 2011: NUCLEIC ACID AMPLIFICATION
- Table 67 : PATENTS ISSUED BETWEEN 2005 AND 2011: BLOOD TREATMENTS
- Table 68 : PATENTS ISSUED BETWEEN 2005 AND 2011: ADDITIONAL POTENTIAL
PRODUCTS
List of Figures
- Figure 1 : TYPES OF BLOOD SCREENING TESTS
- Figure 2 : PROJECTED GLOBAL MARKET FOR BLOOD TYPING AND TESTING, 2010 AND
2015
- Figure 3 : PLASMA PRODUCTS MARKET SHARE, BY COMPANY, 2010
- Figure 4 : LEADING FACTOR VIII MANUFACTURERS, 2010
- Figure 5 : GLOBAL SALES OF FACTOR VIIA, BY GEOGRAPHIC REGION, 2010
- Figure 6 : GLOBAL MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2009 AND 2015
- Figure 7 : THE BASIC ENZYME IMMUNOASSAY (EIA) PROCESS
|
